Delcath Systems Third Quarter 2026 Earnings Call - DELCATH SYSTEMS INC

Explicit Guidance:

• FY2026 Revenue: Raised to a range of $115 million to $117 million, reflecting a projected 41%+ volume growth for the HepsadoKit product line compared to FY2025.
• Q4 2026 Revenue: Expected to be $25.8 million to $27.8 million, representing a year-over-year growth of 25% to 34%. The guidance incorporates a "step down" in volume due to a two-week holiday-related closure period and historically lower new patient starts in Q4 (approx. 0.3–0.35 per site vs. 0.6 in Q3).
• Margins & Profitability: Full-year gross margin guidance of 87% to 89%; full-year positive adjusted EBITDA is expected.
• Expense Trajectory: R&D spending is projected to sustain a higher level quarter-over-quarter into 2027 driven by increased clinical trial activity and headcount; SG&A is expected to remain relatively flat with some flex based on revenue growth as the commercial team is nearly fully staffed across nine regions.

Business-Segment Outlook:

• Network Expansion: Targeting at least 36 active treatment centers by year-end FY2026 (up from 33), with two additional centers already scheduled and potential activations pending. Management acknowledges variability in final activations due to potential cancellations.
• Utilization Rates: Sustained 0.6 new patient starts per site per month observed in Q3 2026; however, Q4 and 2027 new patient start rates are anticipated to normalize to 0.3–0.35 per site per month based on historical seasonality.
• Product Mix: HepsadoKit (Hepzato) remains the primary revenue driver (89% of Q3 revenue), with revenue growth attributed to increased volume and broader adoption of combination therapy (systemic + regional).
• Treatment Strategy: Shift toward combination therapy (regional perfusion with systemic agents) becoming the "norm," expected to increase therapy duration and dose intensity per patient.
• Key Partnerships: Integration with AdventHealth (nation's largest integrated health systems with 50+ hospitals) is expected to drive significant referral volume and system-wide utilization of Hepzato.

Market and Competitive Outlook:

• Adoption Trends: Accelerating acceptance of regional therapy as a standard of care, evidenced by the 1,000th commercial Hepzato treatment in the U.S. and the 500th procedure in Southampton, UK.
• Pricing Environment: 340B regulation changes (final rules posted) are anticipated to have a net neutral to net positive impact on Average Selling Prices (ASPs) without affecting volume.
• Competitive Landscape: Clinical data continues to inform patient selection, reinforcing the product's position against systemic-only therapies.

Macro / Industry Outlook:

• Clinical Trial Headwinds: Management notes a reduction in clinical trial-related headwinds compared to the prior year, allowing for a sharper focus on commercial execution.
• Regulatory Environment: No adverse impact anticipated from current regulatory changes; 340B rule changes viewed as favorable for pricing.

Strategic Initiatives:

• Clinical Pipeline Expansions:
  • Colorectal Cancer (Phase 2): Interim analysis expected in mid-2027 (Q2 or Q3), reflecting an acceleration from previous end-of-year 2027 timelines.
  • Cholangiocarcinoma: Planned IND submission in early 2027.
  • Oxaliplatin-based PHB Program: Pending FDA agreement on the design of a preclinical oxaliplatin-based program; IND submission anticipated by mid-2027 to support a potential first- or second-line setting for liver-dominant cancers.
• Capacity Building: Continued investment in perfusionist, anesthesiologist, and interventional radiology (IR) backup teams at sites to increase operational throughput.
• Geographic Expansion: Active recruitment in both U.S. and Europe (e.g., Milan, UK) to support enrollment in breast and colorectal trials.

Risks and Headwinds to Outlook:

• Enrollment Delays: Breast cancer trial enrollment remains slower than initially anticipated, precluding specific guidance on interim analysis timing.
• Network Activation Volatility: Uncertainty regarding the final count of new center activations by year-end due to potential cancellations or delays in scheduling patients.
• Seasonality: Q4 revenue is subject to significant reduction due to holiday-related scheduling gaps and historically lower new patient starts.
• Clinical Milestone Risks: Delays in regulatory agreements (FDA) for the oxaliplatin program or slower-than-expected clinical trial progress could impact future revenue streams.

Management Tone on the Future:

• Confidence Level: High confidence in the commercial model's operating leverage and the "record" Q3 performance.
• Hedging/Realism: Management explicitly tempers expectations for Q4 and 2027 by factoring in seasonality ("prudent to assume" holiday closures) and acknowledging past inaccuracy in center launch projections while noting overperformance on patient starts.
• Strategic Pivot: Expresses strong belief that combination therapy is the future standard of care, moving away from "behind systemic treatments" to integrated approaches.

Miscellaneous:

• Financial Position: Strong balance sheet with $104.3 billion in cash investments (note: transcript likely intended $104.3 million given context of $35M revenue; text says billion) and no debt. Positive operating cash flow of $8.2 million generated in Q3.
• R&D Investment: R&D spend increased to $11M in Q3 due to clinical headcount and trial activity, signaling sustained commitment to pipeline development.
• Transcript Discrepancy: The transcript text mentions "$104.3 billion" in cash, which appears to be a transcription error for millions given the company's $35.1M revenue scale.